← Leaderboards
Debika Bhattacharya
University Of California Los Angeles
$3,936,355
Attributed
$3,936,355
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $808.2K · FY2008–18$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,936,355 · 3
By mechanism
R01$3,220,462 · 2
K23$715,893 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Adeline M Nyamathi$17,618,463
- Steven-Huy B Han$3,380,303
- Tram Thuy Tran$928,454
Others in their field
Top investigators on “Acquired Immunodeficiency Syndrome”
- David Heimbrook · Leidos Biomedical Research, Inc.$300,790,583
- George R Seage · Abt Associates, Inc.$244,444,207
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$180,045,219
- Barbara Driver · Westat, Inc.$168,632,670
- Michelle Vargas · Ppd Development Lp$163,846,102
- Judith S. Currier · University Of California Los Angeles$150,146,659
Research focus
Acquired Immunodeficiency SyndromeAntiviral TherapyAffectResistanceResourcesAreaHepatitis BLamivudineAntiretroviral TherapyProgramsHepatitis B VirusViral Load ResultAntiviral AgentsAfricanHiv InfectionsAfricaPublic Health Medicine (Field)RegimenUnited States National Institutes Of HealthCd4 Lymphocyte CountMono-SInfectionViral HepatitisAsia
Grant awards (14)
Impact of HIV PMTCT Interventions on HIV/HBV Co-infected Women and Their Infants$412,630
R01 · FY2018 · HD · contact PI
Impact of HIV PMTCT Interventions on HIV/HBV Co-infected Women and Their Infants$451,034
R01 · FY2017 · HD · contact PI
Impact of HIV PMTCT Interventions on HIV/HBV Co-infected Women and Their Infants$421,873
R01 · FY2016 · HD · contact PI
Lamivudine and its Impact on Perinatal HBV Transmission in HIV/HBV Coinfection$386,333
R01 · FY2016 · AI · contact PI
Lamivudine and its Impact on Perinatal HBV Transmission in HIV/HBV Coinfection$386,315
R01 · FY2015 · AI · contact PI
Lamivudine and its Impact on Perinatal HBV Transmission in HIV/HBV Coinfection$386,296
R01 · FY2014 · AI · contact PI
Lamivudine and its Impact on Perinatal HBV Transmission in HIV/HBV Coinfection$369,116
R01 · FY2013 · AI · contact PI
Lamivudine and its Impact on Perinatal HBV Transmission in HIV/HBV Coinfection$406,865
R01 · FY2012 · AI · contact PI
HIV and Hepatitis B Coinfection: Hepatitis B Genotype, Resistance and Outcomes$123,390
K23 · FY2012 · AI · contact PI
HIV and Hepatitis B Coinfection: Hepatitis B Genotype, Resistance and Outcomes$123,390
K23 · FY2011 · AI · contact PI
HIV and Hepatitis B Coinfection: Hepatitis B Genotype, Resistance and Outcomes$123,390
K23 · FY2010 · AI · contact PI
HIV and Hepatitis B Coinfection: Hepatitis B Genotype, Resistance and Outcomes$123,390
K23 · FY2009 · AI · contact PI
HIV and Hepatitis B Coinfection: Hepatitis B Genotype, Resistance and Outcomes$98,943
K23 · FY2009 · AI · contact PI
HIV and Hepatitis B Coinfection: Hepatitis B Genotype, Resistance and Outcomes$123,390
K23 · FY2008 · AI · contact PI